# EDGAR Filing Document

**Accession Number:** 0001055726
**File Stem:** 0001055726-23-000004
**Filing Date:** 2023-2
**Character Count:** 8259
**Document Hash:** 03af3a92cae4162089ef7b05b1ca9a46
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001055726-23-000004.hdr.sgml**: 20230228

**ACCESSION NUMBER**: 0001055726-23-000004

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230226

**FILED AS OF DATE**: 20230228

**DATE AS OF CHANGE**: 20230228

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Weiner David B.
- **CENTRAL INDEX KEY:** 0001669080

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-14888
- **FILM NUMBER:** 23687787

**MAIL ADDRESS:**
- **STREET 1:** 717 BEACOM LANE
- **CITY:** MERION STATION
- **STATE:** PA
- **ZIP:** 19066-1603
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INOVIO PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001055726
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 330969592
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 6769 MESA RIDGE RD.
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 8584103134

**MAIL ADDRESS:**
- **STREET 1:** 6769 MESA RIDGE RD.
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INOVIO BIOMEDICAL CORP
- **DATE OF NAME CHANGE:** 20050404

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GENETRONICS BIOMEDICAL CORP
- **DATE OF NAME CHANGE:** 20011116

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GENETRONICS BIOMEDICAL LTD
- **DATE OF NAME CHANGE:** 19980213

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Weiner David B.<br><sub>(Last) (First) (Middle)</sub><br>660 W. GERMANTOWN PIKE<br>SUITE 110<br><sub>(Street)</sub><br>PLYMOUTH MEETING, PA 19462<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-02-26 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>INOVIO PHARMACEUTICALS, INC. [ INO ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-02-26 |  | M |  | 11667 | A | <sup>(1)</sup> | 904292 | D |  |
| Common Stock | 2023-02-26 |  | M |  | 11667 | A | <sup>(2)</sup> | 915959 | D |  |
| Common Stock | 2023-02-27 |  | S<sup>(3)</sup> |  | 11668 | D | $1.28 | 904291 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Unit | <sup>(1)</sup> | 2023-02-26 |  | M |  |  | 11667 | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 11667.0 | $0 | 11666 | D |  |
| Restricted Stock Unit | <sup>(2)</sup> | 2023-02-26 |  | M |  |  | 11667 | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 11667.0 | $0 | 23333 | D |  |
| Common Stock Option | $1.24 | 2023-02-27 |  | A |  | 60000 |  | 2023-02-27<sup>(4)</sup> | 2033-02-27 | Common Stock | 60000.0 | $0 | 60000 | D |  |
| Restricted Stock Unit | <sup>(5)</sup> | 2023-02-27 |  | A |  | 35000 |  | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 35000.0 | $0 | 35000 | D |  |

---

### Footnotes:

(1) Each restricted stock unit represents a contingent right to receive one share of common stock.  On February 26, 2021, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2022; 11,667 shares vested on February 26, 2023; and 11,666 shares will vest on February 26, 2024.  Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

(2) Each restricted stock unit represents a contingent right to receive one share of common stock.  On February 26, 2022, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2023; 11,667 shares will vest on February 26, 2024; and 11,666 shares will vest on February 26, 2025.  Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

(3) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 13, 2022.

(4) The vesting schedule for the 60,000 options is as follows: 15,000 shares vested on February 27, 2023; 15,000 shares will vest on February 26, 2024; 15,000 shares will vest on February 26, 2025; and 15,000 shares will vest on February 26, 2026.

(5) Each restricted stock unit represents a contingent right to receive one share of common stock.  On February 27, 2023, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares will vest on February 26, 2024; 11,667 shares will vest on February 26, 2025; and 11,666 shares will vest on February 26, 2026.  Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

**Signature:** /s/ David B. Weiner  
**Date:** 2023-02-28

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**